Methods of assigning a COVID pathological type based on a cytokine/chemokine panel
US12228580B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2022 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Jan 13, 2043 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of assigning a COVID pathological type for a subject suffering from COVID-19 are provided. Aspects of the methods include assigning a COVID pathological type for the subject based on a determined quantitative, multiplex cytokine/chemokine panel in a test sample from the subject. Also provided are methods of treating a subject (e.g., a long hauler subject) for chronic COVID-19. Aspects of such methods include administering to the long hauler subject a CCR5/CCL5 interaction inhibitor to treat the long hauler subject. Also provided are compositions for use in practicing the methods. The methods and compositions find use in a variety of applications, including patient stratification, treatment and therapy determination and therapy response assessment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.